Now I have all the information I need. Let me produce the final consolidated review.

## Summary

This paper proposes SimBOL, a framework for localizing the site of origin (SoO) of early ventricular activation from 12-lead ECGs. It combines an onset-based data augmentation strategy (resampling within a physiologically-defined interval around the QRS onset) with a small-scale 1D CNN that balances training data size against model capacity. On a pacing-site dataset of 1,012 LV samples, SimBOL reports a mean coordinate error of ~9.83 mm, which falls under the clinically accepted 10 mm threshold and appears to surpass the previous best method (SVR, 11.80 mm). The paper includes informative ablation studies on augmentation variants and architecture modifications (adding Transformer layers).

## Strengths

- **Onset-based data augmentation is a principled, domain-specific approach to expanding limited ECG training data.** Instead of generic noise or elastic deformations, the method resamples within the interval [t−P/2, t] around the QRS onset, exploiting the quasi-periodic structure of pacing ECGs. The ablation study (Table 1, Section 5.4) shows that this augmentation drives consistent improvement as the resampling rate increases, whereas generic augmentations (noise, scaling, baseline wander) do not further improve performance. This establishes the specific value of onset-based augmentation over generic alternatives. *Evidence: Section 4.1, Figure 4, Table 1.*

- **The data-parameters balance thesis is supported by the Transformer ablation.** Adding a Transformer before the fully connected layer (SimBOL+T) harms performance; adding it at the input (T+SimBOL) achieves similar accuracy but requires ×15 resampling to stabilize, versus ×5 for the smaller SimBOL. This directly demonstrates that the compact architecture is better matched to the available augmented data, validating the central claim about balancing data and model size. *Evidence: Section 5.5, Figure 9.*

- **Honest segment-wise error analysis identifies specific anatomical failure modes.** Figure 7 breaks down performance across 16 ventricular segments and shows that segments 7, 8, 9, and 14 (septum, papillary muscle region) drive the majority of the error. The paper discusses the clinical reasons (conduction system complexity, non-endocardial pacing points) and frames these as directions for future improvement rather than glossing over them. *Evidence: Section 5.3.2, Figure 7.*

- **Minimal input preprocessing requirements.** The model uses raw resampled ECG signals without requiring QRS-integral extraction, beat selection, or pre-training, simplifying the clinical workflow relative to prior approaches (SVR, f-SAE(GRU)). *Evidence: Section 4.1, Section 1.*

## Weaknesses

### Fatal
*None.*

### Major

- **SimBOL is evaluated on a resampled test set (×10 per test sample, ~2,310 evaluations) while baselines appear to be evaluated on the original test set (231 samples), making the headline comparison unfair.** The paper states: "SimBOL resampled each test sample to enhance the generalization capability of the test set. In all experiments, we fixed the resamples rate for the test set at ×10, resulting in 2,310 test samples for evaluation" (Section 5.2.2, "2,3,10" is a parser artifact of 2,310 = 231×10). This constitutes test-time augmentation (TTA) for SimBOL. The paper does not state that baselines (QRSi, CNN, f-SAE(GRU), SVR) received equivalent test-time augmentation. Since the reported improvement over SVR (~2 mm) depends on this TTA (at ×1 training augmentation, SimBOL's 12.94 mm with TTA is still worse than SVR's 11.80 mm without TTA), the central claim of "outperforming the current best method by over 2 mm" is not properly controlled. *Why it matters: The headline quantitative claim is unsupported without apples-to-apples evaluation — either evaluate all methods on the original test set, or apply equivalent TTA to all baselines.*

- **The onset detection procedure for determining the "optimal onset time" (t) is not specified, leaving the core augmentation step underspecified.** The augmentation interval β = [t−P/2, t] depends on knowing t. The paper does not state whether t is manually annotated, automatically detected, or derived from existing annotations in the dataset. If manual, the method inherits inter-operator variability and is not reproducible as described. If automatic, the performance of onset detection must be reported since errors in t propagate to the augmented samples. The adjacent-QT-interval "filling" operation when L > P is also described only vaguely ("filled by adjacent QT interval data") with no discussion of potential discontinuities. *Why it matters: The augmentation is the paper's primary methodological contribution, yet a key component is underspecified and its reliability is unexamined.*

- **The paper repeatedly emphasizes that SimBOL is "small-scale" and balances data and parameters, but never reports the actual number of trainable parameters for SimBOL or any baseline.** This makes it impossible to assess what "small-scale" means quantitatively or to verify the claimed parameter-data balance. The Transformer ablation (Section 5.5) argues indirectly about parameter counts, but without concrete numbers the central thesis remains qualitative. *Why it matters: The data-parameters balance is a core claim; without parameter counts it cannot be evaluated.*

### Minor

- **The clinical threshold claim (< 10 mm) is supported only by the mean error (9.83 mm), with no distributional metrics reported.** Clinical acceptance typically requires coverage statistics (e.g., 95th percentile < 10 mm, or proportion of cases under threshold). The reported variance (0.19 mm) describes stability across random seeds, not the spread of individual prediction errors. Many predictions could exceed 10 mm even if the mean is below the threshold. *Evidence: Section 5.3.1.*

- **No statistical significance test is performed for the comparison against SVR.** Given the small test set (231 original samples) and the reported variance across runs, the ~2 mm gap may or may not be significant. A paired bootstrap or Wilcoxon test would strengthen the claim. *Evidence: Section 5.3.1.*

- **The test set is not fully representative of the label distribution due to the split strategy** (single-sample labels only in training). This means segments with only one clinical sample never appear in the test set, potentially overestimating generalization. The paper acknowledges this implicitly but does not analyze performance on the undersampled regions. *Evidence: Section 5.2.1.*

### Trivial
*None.*

## Nice-to-Haves

- Evaluate a simple MLP or LSTM trained on raw signals as an additional baseline to isolate the contribution of the 1D CNN architecture itself (vs. the augmentation driving all gains).
- Report 16-segment classification accuracy (predicted segment vs. true segment) in addition to coordinate distance, as this is more clinically interpretable for electrophysiologists.
- Investigate model behavior on triangles with zero training samples to strengthen the generalization claim.
- The section on differences between ECG and speech signals (Section 2.2) is tangential to the paper's core contribution and could be trimmed or removed.

## Removed Points

These points were raised by reviewers but removed or demoted after verification against the paper:

- **"ODA alone and None yield the same error is suspicious"** — At ×1 resampling, ODA with no resampling is equivalent to the original signal (no augmentation applied), so identical results are expected and confirm correct experimental setup. Removed as a misunderstanding.
- **"Section 2.2 (ECG vs. Speech) is tangential"** — Subjective presentation opinion, not a methodological weakness. Removed.
- **"Generic LV geometry may not be clinically realistic"** — Scope creep beyond the paper's stated use of a standard resource. Removed.
- **"Missing related works"** — As meta-reviewer, I cannot verify missing citations. Removed per guidelines.
- **Formatting/presentation nitpicks** (e.g., "2,3,10" parser artifact) — Removed per hard rules on parser errors.
- **"Overstating simplicity"** — Subjective framing criticism. Removed.
- **"Weakness reproducibility" about undisclosed hyperparameters** — Training hyperparameters are reported (Section 5.2.3). Removed.

## Novel Insights

None beyond the paper's own contributions.

## Suggestions

1. **Fix the evaluation protocol.** Report SimBOL's performance on the original 231 test samples without test-time augmentation, so all methods are compared on identical data. If TTA is retained as integral to SimBOL, apply equivalent TTA to baselines (or justify why it cannot apply) and show that the gap persists.

2. **Specify the onset detection method.** Clarify how the "optimal onset time" t is obtained (manual annotation, automatic detection, or dataset-provided). If manual, acknowledge as a limitation. If automatic, report detection accuracy and sensitivity analysis.

3. **Report model parameter counts** for SimBOL and all baselines. Make the "small-scale" claim quantitative.

4. **Provide distributional error metrics** (e.g., 95th percentile, proportion under 10 mm) to support the clinical acceptability claim.

5. **Add a statistical significance test** (paired bootstrap or Wilcoxon) for the SimBOL vs. SVR comparison.

## Score and Decision

MY FINAL SCORE: <score>5.5</score>
MY FINAL DECISION: <decision>Reject</decision>